Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07231627 · ClinicalTrials.gov registry record · NA
AI Algorithm-Informed Biopsy for Prostate Cancer Detection With Indeterminate and Low-Risk Prostate MRI Lesions
A NA study, sponsored by University of Arkansas.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT07231627 is a NA study that is actively recruiting participants, run by University of Arkansas. The registered enrollment target is 50 participants.
The verdict
NCT07231627, a NA study, is actively recruiting participants, sponsored by University of Arkansas.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
Use of AI algorithm for PCa detection is feasible, and AI-informed biopsies (AI-targeted and perilesional biopsy) improves csPCa detection in patients with indeterminate MRI lesions and in patients with low-risk MRI lesions and high-risk clinical features.
Interventions
- DEVICE Bi-parametric MRI-based cascaded deep-learning AI algorithm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-06 |
| Est. Completion | 2029-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07231627
The ClinicalTrials.gov registry entry for NCT07231627 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bi-parametric MRI-based cascaded deep-learning AI algorithm is the first listed.
NCT07231627 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07231627 about?
NCT07231627 is a clinical study titled "AI Algorithm-Informed Biopsy for Prostate Cancer Detection With Indeterminate and Low-Risk Prostate MRI Lesions". Use of AI algorithm for PCa detection is feasible, and AI-informed biopsies (AI-targeted and perilesional biopsy) improves csPCa detection in patients with indeterminate MRI lesions and in patients with low-risk MRI lesions and high-risk clinical features.
What is the current status of trial NCT07231627?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2026-06. Estimated completion is 2029-01.
What interventions are being tested in trial NCT07231627?
The interventions under investigation include: Bi-parametric MRI-based cascaded deep-learning AI algorithm (DEVICE).
Who is sponsoring clinical trial NCT07231627?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.